{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T02:01:58Z","timestamp":1788055318401,"version":"build-2784847793"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","funder":[{"name":"Fresenius Medical Care Renal Therapies Group"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2020,4]]},"abstract":"\n Background<\/jats:title>\n Combination therapy with multiple phosphate binders is prescribed to reduce elevated serum phosphorus (sP) concentrations among patients on maintenance hemodialysis. Sucroferric oxyhydroxide (SO), an iron-based phosphate binder, has demonstrated efficacy at reducing sP while also being associated with a low pill burden. Whereas the effects of SO monotherapy have been well characterized in clinical trials and observational cohorts, little is known about the effects of SO-containing combination therapy.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Patients on hemodialysis (\n N<\/jats:italic>\n =234) at Fresenius Kidney Care (FKC) who received \u2265120 days of uninterrupted phosphate binder combination therapy with SO were included in this retrospective study. Patient data were censored after SO discontinuation, end of care at FKC, or completion of 12 months of follow-up. Quarterly (Q) changes in phosphate binder pill burden, mean sP, and proportion of patients achieving National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI)\u2013recommended sP levels (\u22645.5 mg\/dl) were compared between baseline (\u2212Q1) and follow-up (Q1\u2013Q4).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Phosphate binder combination therapy with SO was associated with significant increase in the proportion of patients with sP \u22645.5 mg\/dl (from 19% at baseline to up to 40% at follow-up;\n P<\/jats:italic>\n <0.001) and reduction in sP at all postbaseline time points (from 6.7 mg\/dl to 6.2\u20136.3 mg\/dl;\n P<\/jats:italic>\n <0.001). Patients on calcium acetate (\n N<\/jats:italic>\n =54) and sevelamer (\n N<\/jats:italic>\n =94) who added SO therapy at follow-up resulted in a \u2265250% increase in patients achieving sP \u22645.5 mg\/dl (all\n P<\/jats:italic>\n <0.001). Whereas mean phosphate binder pill burden increased with initiation of phosphate binder combination therapy with SO (15.8 pills\/d at Q1 versus 12.3 pills\/d at \u2212Q1), continued use of SO was associated with down-titration of non-SO phosphate binders such that, by Q4, mean total PB pill burden reduced to 12.3 pills\/d.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n For patients on hemodialysis with uncontrolled hyperphosphatemia, combination therapy with SO may allow for sustained improvements in sP control without adversely affecting phosphate binder pill burden.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0000332019","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T21:30:43Z","timestamp":1584999043000},"page":"263-272","source":"Crossref","is-referenced-by-count":5,"title":["Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients"],"prefix":"10.34067","volume":"1","author":[{"given":"Donald A.","family":"Molony","sequence":"first","affiliation":[{"name":"Division of Renal Diseases and Hypertension, Center for Clinical Research and Evidence-Based Medicine, McGovern Medical School University of Texas, Houston, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhya","family":"Parameswaran","sequence":"additional","affiliation":[{"name":"Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda H.","family":"Ficociello","sequence":"additional","affiliation":[{"name":"Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudy","family":"Mullon","sequence":"additional","affiliation":[{"name":"Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kossmann","sequence":"additional","affiliation":[{"name":"Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,4,30]]},"reference":[{"key":"B1-20230821","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ki.2008.130","article-title":"Hyperphosphatemia of chronic kidney disease","volume":"74","author":"Hruska","year":"2008","journal-title":"Kidney Int"},{"key":"B2-20230821","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.kint.2017.11.036","article-title":"Prevention and treatment of hyperphosphatemia in chronic kidney disease","volume":"93","author":"Vervloet","year":"2018","journal-title":"Kidney Int"},{"key":"B3-20230821","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2215\/CJN.05130610","article-title":"Prevention and control of phosphate retention\/hyperphosphatemia in CKD-MBD: What is normal, when to start, and how to treat?","volume":"6","author":"Martin","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B4-20230821","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMra0912522","article-title":"Oral phosphate binders in patients with kidney failure","volume":"362","author":"Tonelli","year":"2010","journal-title":"N Engl J Med"},{"key":"B5-20230821","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"B6-20230821","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrneph.2016.164","article-title":"The role of phosphate in kidney disease","volume":"13","author":"Vervloet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B7-20230821","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/ndt\/gfn613","article-title":"Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease","volume":"24","author":"Covic","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B8-20230821","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jama.2011.308","article-title":"Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-analysis","volume":"305","author":"Palmer","year":"2011","journal-title":"JAMA"},{"key":"B9-20230821","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.2215\/CJN.11931116","article-title":"Association of parameters of mineral bone disorder with mortality in patients on hemodialysis according to level of residual kidney function","volume":"12","author":"Wang","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B10-20230821","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1681\/ASN.2014050472","article-title":"Uncorrected and albumin-corrected calcium, phosphorus, and mortality in patients undergoing maintenance dialysis","volume":"26","author":"Rivara","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B11-20230821","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/ndt\/gfv099","article-title":"Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: The COSMOS study","volume":"30","author":"Fern\u00e1ndez-Mart\u00edn","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"B12-20230821","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10157-016-1360-y","article-title":"Management of phosphorus load in CKD patients","volume":"21","author":"Taketani","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"B13-20230821","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cqn.2014.03.003","article-title":"Dietary management of hyperphosphatemia in chronic kidney disease","volume":"3","author":"Sinha","year":"2014","journal-title":"Clinical Queries: Nephrology."},{"key":"B14-20230821","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/sdi.12439","article-title":"Removal of phosphorus by hemodialysis","volume":"28","author":"Daugirdas","year":"2015","journal-title":"Semin Dial"},{"issue":"Suppl 3","key":"B15-20230821","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B16-20230821","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.ajkd.2011.12.025","article-title":"Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Evaluation of possible confounding by nutritional status","volume":"60","author":"Lopes","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B17-20230821","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1681\/ASN.2008060609","article-title":"Phosphorus binders and survival on hemodialysis","volume":"20","author":"Isakova","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B18-20230821","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/ki.2013.185","article-title":"Use of phosphate-binding agents is associated with a lower risk of mortality","volume":"84","author":"Cannata-And\u00eda","year":"2013","journal-title":"Kidney Int"},{"key":"B21-20230821","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3949\/ccjm.85a.17054","article-title":"Phosphorus binders: The new and the old, and how to choose","volume":"85","author":"Sekar","year":"2018","journal-title":"Cleve Clin J Med"},{"key":"B22-20230821","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/ndt\/gft280","article-title":"Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis","volume":"29","author":"Wang","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B23-20230821","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Chiu","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B25-20230821","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10157-016-1299-z","article-title":"Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: A randomized, placebo-controlled, double-blind, Phase II study [published correction appears in Clin Exp Nephrol 21: 523, 2017]","volume":"21","author":"Koiwa","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"B26-20230821","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/nep.12891","article-title":"Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open-label, multicentre, 12-week phase III study","volume":"22","author":"Koiwa","year":"2017","journal-title":"Nephrology (Carlton)"},{"key":"B27-20230821","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/hdi.12663","article-title":"Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients","volume":"22","author":"Sprague","year":"2018","journal-title":"Hemodial Int"},{"key":"B28-20230821","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/ndt\/gfw460","article-title":"One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis","volume":"32","author":"Floege","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B29-20230821","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"B30-20230821","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1053\/j.jrn.2018.11.002","article-title":"One-year historical cohort study of the phosphate binder sucroferric oxyhydroxide in patients on maintenance hemodialysis","volume":"29","author":"Kendrick","year":"2019","journal-title":"J Ren Nutr"},{"key":"B31-20230821","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5414\/CN109021","article-title":"Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data","volume":"88","author":"Coyne","year":"2017","journal-title":"Clin Nephrol"},{"key":"B32-20230821","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/IJNRD.S182747","article-title":"Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide","volume":"12","author":"Gray","year":"2019","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"B33-20230821","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ekir.2017.10.003","article-title":"Efficacy and safety of sucroferric oxyhydroxide and calcium carbonate in hemodialysis patients","volume":"3","author":"Koiwa","year":"2017","journal-title":"Kidney Int Rep"},{"key":"B34-20230821","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/ndt\/gfy091","article-title":"Hyperphosphataemia: Which phosphate binder?","volume":"33","author":"Vervloet","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B35-20230821","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3109\/0886022X.2012.718724","article-title":"The adequacy of phosphorus binder prescriptions among American hemodialysis patients","volume":"34","author":"Huml","year":"2012","journal-title":"Ren Fail"},{"key":"B36-20230821","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2147\/PPA.S145648","article-title":"Phosphate-control adherence in hemodialysis patients: Current perspectives","volume":"12","author":"Umeukeje","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"B37-20230821","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hdi.12315","article-title":"Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS","volume":"20","author":"Fissell","year":"2016","journal-title":"Hemodial Int"},{"key":"B38-20230821","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2369-14-153","article-title":"Hyperphosphatemia in patients with ESRD: Assessing the current evidence linking outcomes with treatment adherence","volume":"14","author":"Covic","year":"2013","journal-title":"BMC Nephrol"},{"key":"B39-20230821","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12882-015-0205-3","article-title":"Meal phosphate variability does not support fixed dose phosphate binder schedules for patients treated with peritoneal dialysis: A prospective cohort study","volume":"16","author":"Leung","year":"2015","journal-title":"BMC Nephrol"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000332019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:56:43Z","timestamp":1786478203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000332019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000332019","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}